Exhibit 99.1 Exicure, Inc. Reports First Quarter 2024 Financial Results CHICAGO, IL — June 17, 2024 — Exicure, Inc. (Nasdaq: XCUR, the "Company"), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alter ...